文献速递姑息放疗与转移瘤

转移性癌症患者接受多程重复放疗的疗效与安全性分析

Efficacy and safety analysis in metastatic cancer patients treated with multiple courses of repeat radiation therapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-10-02

本回顾性队列研究纳入2011至2019年在本机构接受至少五次重复放疗的112例患者共660程放疗,分析治疗特征、生存、安全性和疗效。首次放疗后中位生存3.6年,548程(83.0%)观察到放疗反应,21程(3.2%)出现CTCAE≥3级毒性。放疗程数增加(HR 1.30)、Type 1再照射(HR 3.50)和KPS≤80%(HR 2.02)与显著更差的治疗反应相关,毒性率随放疗程数增加保持稳定。

要点

  • 112例患者共接受660程放疗,以肺癌(41.9%)和恶性黑色素瘤(8.9%)最常见。
  • 首次放疗后中位生存3.6年,548程(83.0%)观察到放疗反应,21程(3.2%)出现CTCAE≥3级毒性。
  • 放疗程数增加(HR 1.30)、Type 1再照射(HR 3.50)和KPS≤80%(HR 2.02)与显著更差的治疗反应相关。

核心结论

  • 多程重复放疗维持了高反应率联合合理安全性的有利治疗比。

研究设计与样本

  • 回顾性队列研究,筛查2011年至2019年在本机构接受至少五次重复照射的所有患者,共纳入112例患者、660程放疗。
  • 再照射类型根据ESTRO-EORTC共识指南分类。

主要发现

  • 最常见原发肿瘤为肺癌41.9%(n=47)和恶性黑色素瘤8.9%(n=10)。
  • 最常见再照射类型为重复照射309例(46.8%)和Type 2再照射113例(17.1%)。
  • 首次放疗后中位生存3.6(0.3-13.4)年。
  • 548例(83.0%)观察到放疗反应,21例(3.2%)出现CTCAE≥3级毒性。
  • 放疗程数增加(HR 1.30,p<0.0001)、Type 1再照射(HR 3.50,p=0.008)和KPS≤80%(HR 2.02,p=0.002)与显著更差的治疗反应相关;毒性率随放疗程数增加保持稳定。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Due to advances in oncology, a growing proportion of patients is treated with repetitive courses of radiotherapy. The aim of this study is to analyze whether radiotherapy maintains its safety and efficacy profile in patients treated with multiple repeat courses of irradiation. MATERIAL AND METHODS: All patients treated between 2011 and 2019 at our institution were screened for a minimum of five repeat irradiation courses, to analyze treatment characteristics, survival, safety and efficacy. The type of re-irradiation was classified according to ESTRO-EORTC consensus guidelines. RESULTS: A total of n = 112 patients receiving n = 660 radiotherapy courses were included in this retrospective cohort study. The most frequent primary tumors were lung cancer in 41.9 % (n = 47) and malignant melanoma in 8.9 % (n = 10). The most frequent re-irradiation types were repeat irradiation and Type 2 re-irradiation in 309 (46.8 %) and 113 (17.1 %) cases, respectively. Median survival after the first course of radiotherapy was 3.6 (0.3-13.4) years. Response to radiotherapy was observed in 548 (83.0 %) cases and CTCAE toxicity grade ≥ 3 was observed in 21 (3.2 %) cases. An increasing number of RT courses (HR: 1.30, p=<0.0001), Type 1 re-irradiation (HR 3.50, p = 0.008) and KPS ≤ 80 % (HR: 2.02, p = 0.002) were associated with significantly worse treatment responses. Toxicity rates remained stable with increasing numbers of RT courses. CONCLUSION: Multiple courses of repeat radiotherapy maintain a favorable therapeutic ratio of high response combined with reasonable safety profile.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ahmadsei M, Christ SM, Kroese TE, et al. Efficacy and safety analysis in metastatic cancer patients treated with multiple courses of repeat radiation therapy. Clin Transl Radiat Oncol. 2023. PMID: 37867613. doi:10.1016/j.ctro.2023.100687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。